Duloxetine and the symptoms and quality of life of patients with irritable bowel syndrome

Phase 2

• Conditions: Condition 1: Irritable Bowel Syndrome. Condition 2: Quality of life. Condition 3: Stress, anxiety and depression.; Irritable bowel syndrome; Acute stress reaction; F43.0

• Registration Number: IRCT20190404043159N1
• Lead Sponsor: Esfahan University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 6 October 2020

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

Men and women aged 18 to 65 years
Diagnosis of irritable bowel syndrome by a gastroenterologist
Moderate to severe symptoms
Conscious consent to participate in the study
Have a minimum literacy
Absence of depressive disorders, bipolar disorder or psychotic disorders

Exclusion Criteria

Diagnosis of any organic disease
Failure to take medication regularly
Failure to complete the questionnaire
Severe side effects
Patient request to leave the study

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Quality of life score. Timepoint: Before and one week after interventions. Method of measurement: Quality of Life Questionnaire for Patients with Irritable Bowel Syndrome.;Anxiety, depression and stress score. Timepoint: Before and one week after interventions. Method of measurement: By The Depression, Anxiety, and Stress Scale – 21 (DASS-21) questionnaire.;Severity of symptoms. Timepoint: Before and one week after interventions. Method of measurement: Irritable Bowel Syndrome Symptoms Severity Questionnaire.